An extension study of the safety and anti-leukemic effects of imatinib mesylate in adult patients with Ph [Philadelphia] + leukemia.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Leukaemia
- Focus Therapeutic Use
- Sponsors Novartis
- 15 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 23 Apr 2013 Planned End Date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 27 Apr 2012 Planned End Date changed from 1 Dec 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.